Telisotuzumab vedotin (Teliso‐V; ABBV‐399) is an antibody‐drug conjugate (ADC) comprised of the c‐Met targeting antibody telisotuzumab (ABT‐700) conjugated to the potent cytotoxic monomethyl auristatin E (MMAE). Teliso‐V has been evaluated for treating solid tumors and is approved for adults with locally‐advanced or metastatic non‐squamous non‐small cell lung cancer with high c‐Met protein overexpression (≥50% tumor cells with strong [+3] staining; determined by FDA‐approved test), who have received prior systemic therapy. Here, physiologically‐based pharmacokinetic (PBPK) modeling was utilized to evaluate Teliso‐V drug‐drug interaction (DDI) potential. A published PBPK‐model for MMAE as the primary metabolite and a newly‐developed telisotuzumab model from existing pre‐clinical and clinical trial data were used to create a novel Teliso‐V PBPK‐model. Unconjugated MMAE release was modeled with drug‐to‐antibody ratio‐specific deconjugation rates, with non‐specific and catabolic clearance added to capture half‐life and overall PK profile. The Teliso‐V model was calibrated and validated using observed clinical trial data, requiring dose‐normalized exposure %PEs ≤50%. CYP3A‐mediated DDI simulations demonstrated that when Teliso‐V was modeled as the victim, a 43% increase and 70% decrease in MMAE AUC were predicted with ketoconazole (strong CYP3A4‐inhibitor) and rifampin (strong CYP3A4‐inducer) coadministration, respectively. DDI magnitude was comparable to that observed between another approved ADC with the same MMAE payload (brentuximab vedotin) and ketoconazole and rifampin. The current PBPK simulations demonstrated a lack of perpetrator effect of Teliso‐V on midazolam, a sensitive CYP3A substrate. The current analysis provides important information on Teliso‐V DDI potential and further demonstrates the utility of PBPK models, particularly in oncology, where dedicated DDI studies are challenging.
The aim of this analysis was to use a physiologically based pharmacokinetic (PBPK) model to predict the impact of changes in dissolution rates on elagolix exposures and define clinically relevant acceptance criteria for dissolution. Varying in vitro dissolution profiles were utilized in a PBPK model to describe the absorption profiles of elagolix formulations used in Phase 3 clinical trials and for the to be marketed commercial formulations. Single dose studies of 200 mg elagolix formulations were used for model verification under fasted conditions. Additional dissolution scenarios were evaluated to assess the impact of dissolution rates on elagolix exposures. Compared to the Phase 3 clinical trial formulation, sensitivity analysis on dissolution rates suggested that a hypothetical scenario of ∼75% slower dissolution rate would result in 14% lower predicted elagolix plasma exposures, however, the predicted exposures are still within the bioequivalence boundaries of 0.8–1.25 for both Cmax and AUC. A clinically verified PBPK model of elagolix was utilized to evaluate the impact of wider dissolution specifications on elagolix plasma exposures. The simulation results indicated that a slower in vitro dissolution profile, would not have a clinically significant impact on elagolix exposures. These model results informed the setting of wider dissolution specifications without requiring in vivo studies.
Model‐informed drug development (MIDD) entails applying quantitative approaches to assist with decision‐making during drug development and has been used for dose optimization, to inform clinical trial design, and to support clinical trial waivers. With increasing cost and competitiveness in drug development, the use of tools that improve efficiency, like MIDD, is increasingly crucial. A unique case for the successful application of MIDD approaches from early Phase 1 through postapproval for the upadacitinib development program is described herein. Upadacitinib is an orally administered selective Janus kinase inhibitor, which is approved for rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, axial spondylarthritis, nonradiographic axial spondyloarthritis, ulcerative colitis, and Crohn's disease for adults, in addition to recent approvals for polyarticular juvenile idiopathic arthritis and pediatric patients with psoriatic arthritis. Applications and impact of modeling and simulation approaches for informing key development decisions are presented to highlight the success of using MIDD for the clinical development of upadacitinib. The lessons learned can provide a framework for the clinical development of other drugs.
7 April 2026 in CPT: Pharmacometrics & Systems Pharmacology
Cariprazine is a potent D 3 ‐preferring dopamine D 3 /D 2 receptor partial agonist, a serotonin 5‐HT 1A receptor partial agonist, and a serotonin 5‐HT 2B receptor antagonist approved for the treatment of a variety of psychiatric disorders. A clinical study examining short‐term (4 days) drug–drug interactions (DDIs) between cariprazine and ketoconazole, a strong CYP3A4 inhibitor, guided cariprazine dosing adjustment recommendations in concomitant use with CYP3A4 inhibitors in the original US FDA marketing approval. However, didesmethyl‐cariprazine (DDCAR), a major active metabolite of cariprazine, takes 4–8 weeks to reach steady‐state plasma concentration. Therefore, longer term clinical DDI studies would be needed to fully understand cariprazine DDIs but are greatly challenging. Regulatory agencies are increasingly encouraging the use of physiologically based pharmacokinetic (PBPK) modeling to evaluate DDIs. Here, we developed PBPK models of cariprazine, DCAR, and DDCAR that adequately described their plasma exposures across multiple Phase 1 or 2 clinical studies with cariprazine treatment alone or in combination with CYP3A inhibitors ketoconazole or erythromycin. The validated models predicted up to 6.0‐fold, 2.9‐fold, and 1.1‐fold increases in total cariprazine (cariprazine + DCAR + DDCAR) exposure at steady state upon prolonged coadministration of strong, moderate, and weak CYP3A4 inhibitors, respectively. The PBPK models allowed for more optimal cariprazine dose adjustments with short‐term and long‐term concomitant use of strong and moderate CYP3A4 inhibitors. Model predictions led to an update in US prescribing information in November 2024 to inform on optimal cariprazine dose adjustment with concomitant use of CYP3A inhibitors. Updated recommendations had the objective of maintaining treatment efficacy while minimizing drug adverse effect risk.